AR022374A1 - GUM RUBBER MEDICATION SUPPLY SYSTEM FOR NICOTINE - Google Patents

GUM RUBBER MEDICATION SUPPLY SYSTEM FOR NICOTINE

Info

Publication number
AR022374A1
AR022374A1 ARP990104461A ARP990104461A AR022374A1 AR 022374 A1 AR022374 A1 AR 022374A1 AR P990104461 A ARP990104461 A AR P990104461A AR P990104461 A ARP990104461 A AR P990104461A AR 022374 A1 AR022374 A1 AR 022374A1
Authority
AR
Argentina
Prior art keywords
minutes
nicotine
active
supply system
provides
Prior art date
Application number
ARP990104461A
Other languages
Spanish (es)
Original Assignee
Jsr Llc
Fuisz Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/146,696 external-priority patent/US6358060B2/en
Priority claimed from US09/389,339 external-priority patent/US6344222B1/en
Application filed by Jsr Llc, Fuisz Technologies filed Critical Jsr Llc
Publication of AR022374A1 publication Critical patent/AR022374A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Abstract

Un sistema de suministro de goma de mascar que tiene nicotina, goma base y un sistema buffer, con un perfeccionado índice de liberacion para la nicotina.El sistema de suministro resultante proporciona convenientemente un sistema conveniente, confiable, práctico y relativamente indoloro para el suministro de unactivo. El sistema de suministro es capaz de suministrar dosis iniciales y secundarias de un activo reductor del deseo, y otros activos (por ejemplo, nicotina), cuya combinacion rápidamentereduce los deseos, o proporciona algun otro efecto farmacologico, y proporciona el efecto farmacologico o proteccion contradichos deseos durante un período de tiempo prolongado más allá de la dosis inicial. Cabe observarse que el sistema de suministro es capaz de lograr rápidamenteuna concentracion farmacologicamente efectiva del activo (por ejemplo, nicotina) en la corriente sanguínea (por ejemplo, dentro de los 5 minutos o con másconveniencia dentro de los 3 minutos, o en algunos casos, dentro de 1-2 minutos), y además es capaz de mantener la concentracion del activo en la corrientesanguínea a la concentracion farmacologicamente efectiva, o cerca de ella, durante por lo menos 20 minutos después de que comienza el mascado del sistema desuministro, o con más conveniencia, aproximadamente 30 minutos a aproximadamente 50 minutos después de que comienza el mascado.A chewing gum supply system having nicotine, gum base and a buffer system, with an improved release rate for nicotine.The resulting supply system conveniently provides a convenient, reliable, practical and relatively painless system for the supply of an active. The delivery system is capable of delivering initial and secondary doses of a desire-reducing active, and other active ingredients (for example, nicotine), the combination of which rapidly reduces desires, or provides some other pharmacological effect, and provides the pharmacological effect or contradictory protection wishes for a prolonged period of time beyond the initial dose. It should be noted that the delivery system is able to quickly achieve a pharmacologically effective concentration of the asset (for example, nicotine) in the bloodstream (for example, within 5 minutes or more conveniently within 3 minutes, or in some cases, within 1-2 minutes), and is also able to maintain the concentration of the active in the blood stream at the pharmacologically effective concentration, or near it, for at least 20 minutes after the chewing of the delivery system, or with more convenience, approximately 30 minutes to approximately 50 minutes after chewing begins.

ARP990104461A 1998-09-03 1999-09-03 GUM RUBBER MEDICATION SUPPLY SYSTEM FOR NICOTINE AR022374A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/146,696 US6358060B2 (en) 1998-09-03 1998-09-03 Two-stage transmucosal medicine delivery system for symptom relief
IE980991 1998-11-27
US36089699A 1999-07-26 1999-07-26
US09/389,339 US6344222B1 (en) 1998-09-03 1999-09-02 Medicated chewing gum delivery system for nicotine

Publications (1)

Publication Number Publication Date
AR022374A1 true AR022374A1 (en) 2002-09-04

Family

ID=27270586

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990104461A AR022374A1 (en) 1998-09-03 1999-09-03 GUM RUBBER MEDICATION SUPPLY SYSTEM FOR NICOTINE

Country Status (4)

Country Link
AR (1) AR022374A1 (en)
DE (1) DE69938347T2 (en)
DK (1) DK1107730T3 (en)
MY (1) MY124346A (en)

Also Published As

Publication number Publication date
MY124346A (en) 2006-06-30
DE69938347D1 (en) 2008-04-24
DE69938347T2 (en) 2009-04-23
DK1107730T3 (en) 2008-07-14

Similar Documents

Publication Publication Date Title
ATE388687T1 (en) MEDICINAL ADMINISTRATION OF NICOTINE IN THE FORM OF CHEWING GUM
CR6458A (en) VALDECOXIB COMPOSITIONS
CO5060522A1 (en) ADMINISTRATION OF AN ACTIVE AGENT IN AEROSOL
ATE116131T1 (en) AGENTS FOR THE NON-SYSTEMIC ADMINISTRATION OF SEDATIVES AND ANALGESICS.
ATE341309T1 (en) PULMONARY DRUG ADMINISTRATION
KR900701274A (en) Dosage formulations reduce the likelihood of abuse
CY1117668T1 (en) PHARMACEUTICAL RECOMMENDATIONS INCLUDING INSULIN CONTAINED WITH A DICETEPIPERAZINE
DE60044464D1 (en) BUKKALE TRANSMUCOSAL DRUG CLEANING USING A SOLID SOLUTION
AR042937A2 (en) SUSTAINED RELEASE FORMULATIONS FOR GROWTH HORMONE SECRETAGOGS
GT200000041A (en) USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES.
EE9900288A (en) Use of an Oral Pharmaceutical Composition for the manufacture of a medicament for the treatment of erectile dysfunction in men
ES2159525T3 (en) PROTECTION SYSTEM, SAFETY, FOR NEEDLE.
ES2171469T3 (en) COMPOSITION ADMINISTERED BY NASAL AND PREPARATION THAT CONTAINS IT.
KR900009106A (en) Delivery system comprising means for regulating the infiltration of fluid into the system
DK0772452T3 (en) Pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration of factor VIII
BR0115392A (en) Method for the treatment of an interferon-sensitive disease in a warm-blooded animal, method for individualizing the dosages of an interferon in treatment, method for manufacturing a long-term therapeutic effect delivery device of a drug over a period of time, and useful set for delivering a relatively constant amount of a drug
TR200001891T2 (en) ASPB28- Human insulin and its use.
ES2057537T3 (en) DOSING SYSTEM WITH CONTINUOUS EMISSION.
AR020803A1 (en) A COMPOSITION THAT INCLUDES FEXOFENADINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINE
ES2114851T3 (en) USE OF SUSTAINED RELEASE COMPOSITIONS CONTAINING GNRH, LHRH OR DERIVATIVES THEREOF.
CO5200840A1 (en) COMBINATION OF ACTIVE SUBSTANCES WITH CLONIDINE
ES2168241T1 (en) PHARMACEUTICAL PREPARATION CONTAINING TOLPERISONE TO ADMINISTER BY ORAL ROUTE.
PT904067E (en) DEXTROMETORFAN AS AN ANTISUSTIC AGENT TRANSMEDICALLY ADMINISTERED
ES2060685T3 (en) MEDICATION WITH CONTENT OF AZELASTIN WITH CONTROLLED RELEASE OF THE ACTIVE SUBSTANCE.
ES2176805T3 (en) USE OF MIXTURES OF ACTIVE PRODUCTS FOR THE OBTAINING OF HYPOCOLESTERINEMIC AGENTS.

Legal Events

Date Code Title Description
FB Suspension of granting procedure